Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02982902 · ClinicalTrials.gov registry record · Early Phase 1
T Cell Therapy of Opportunistic Cytomegalovirus Infection
A Early Phase 1 study of Cytomegalovirus Infections and Hematopoietic Stem Cell Transplant, sponsored by Mari Dallas.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02982902: Recruiting Early Phase 1 study of Cytomegalovirus Infections and Hematopoietic Stem Cell Transplant, sponsored by Mari Dallas.
NCT02982902 is a Early Phase 1 study of Cytomegalovirus Infections and Hematopoietic Stem Cell Transplant that is actively recruiting participants, run by Mari Dallas. The registered enrollment target is 20 participants, below the 202-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02982902, a Early Phase 1 study of Cytomegalovirus Infections and Hematopoietic Stem Cell Transplant, is actively recruiting participants, sponsored by Mari Dallas.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if a specific type of cell-based immunotherapy, using T-cells from a donor that are specific against cytomegalovirus (CMV) is feasible to treat infections by CMV. Adoptive T-cell therapy is an investigational (experimental) therapy that works by using the blood of a donor and selecting the T-cells that can respond against a specific infectious entity. These selected T-cells are then infused to the patient, to try to give the immune system the ability to fight the infection. Adoptive T-cell therapy is experimental because it is not approved by the Food and Drug Administration (FDA).
Primary Outcome
To determine the feasibility of the intervention, the study will record the incidence of adverse events, including graft versus host disease and other complications will be evaluated using binomial distribution theory and their 95% confidence intervals (CIs) will be also estimated using Wilson's method
Conditions Studied
Interventions
- BIOLOGICAL CMV specific adoptive t-cells
Study Locations (1)
Ohio
- University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-05-27 |
| Est. Completion | 2028-08 |
| Phase | Early Phase 1 |
What NCT02982902 shows while recruiting
NCT02982902 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 202-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (90% lower).
The record links to 3 conditions, with Cytomegalovirus Infections appearing as the primary indexed condition, and to 1 intervention - of which CMV specific adoptive t-cells is the first listed.
NCT02982902 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT02982902 about?
NCT02982902 is a clinical study titled "T Cell Therapy of Opportunistic Cytomegalovirus Infection". The purpose of this study is to determine if a specific type of cell-based immunotherapy, using T-cells from a donor that are specific against cytomegalovirus (CMV) is feasible to treat infections by CMV. Adoptive T-cell therapy is an investigational (experimental) therapy that works by using the b...
What is the current status of trial NCT02982902?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2020-05-27. Estimated completion is 2028-08.
What conditions does trial NCT02982902 study?
This clinical trial studies the following conditions: Cytomegalovirus Infections, Hematopoietic Stem Cell Transplant, Opportunistic Infections.
What interventions are being tested in trial NCT02982902?
The interventions under investigation include: CMV specific adoptive t-cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT02982902?
This trial is sponsored by Mari Dallas, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02982902 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytomegalovirus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02982902's enrollment target sits among peer trials
20 22nd of 24 higher than 1 of 24 other Cytomegalovirus Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cytomegalovirus Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
RECRUITING · Phase 4
-
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
RECRUITING · Phase 2
-
Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study
RECRUITING
-
R-MVST Cells for Treatment of Viral Infections
RECRUITING · Phase 1
-
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
RECRUITING · Phase 1
-
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI